Development of a Dosage Form of the New Antitumor Antibiotic Olivamide


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Methods for selective chemical modification of the antitumor antibiotic olivomycin A(OA) were developed at GINA. The compound olivamide with advantages over starting OA was selected from series of OA analogs. The goal of the present work was to develop a dosage form of the antitumor semi-synthetic antibiotic olivamide that guaranteed the stability and high specific activity of olivamide drug substance and was designed for further comprehensive preclinical studies.

作者简介

A. Tevyashova

G. F. Gause Institute of New Antibiotics (GINA); D. Mendeleev University of Chemical Technology of Russia

编辑信件的主要联系方式.
Email: chulis@mail.ru
俄罗斯联邦, 11/1 Bol’shaya Pirogovskaya St., Moscow, 119021; 9 Miusskaya Sq., Moscow, 125047

E. Bychkova

G. F. Gause Institute of New Antibiotics (GINA)

Email: chulis@mail.ru
俄罗斯联邦, 11/1 Bol’shaya Pirogovskaya St., Moscow, 119021

L. Dezhenkova

G. F. Gause Institute of New Antibiotics (GINA)

Email: chulis@mail.ru
俄罗斯联邦, 11/1 Bol’shaya Pirogovskaya St., Moscow, 119021

A. Shchekotikhin

G. F. Gause Institute of New Antibiotics (GINA); D. Mendeleev University of Chemical Technology of Russia

Email: chulis@mail.ru
俄罗斯联邦, 11/1 Bol’shaya Pirogovskaya St., Moscow, 119021; 9 Miusskaya Sq., Moscow, 125047

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019